Sinovac Biotech Ltd. Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)

BEIJING, July 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, today announced that it has initiated dosing today in its clinical trial of various Panflu vaccine candidates for pandemic influenza A (H1N1). Results are expected in September 2009.

MORE ON THIS TOPIC